News We’re Watching: Illumina Looks At Grail Options, New AdvaMed Digital Health Division, Evolut FX Gets CE Mark
Executive Summary
This week, Illumina responded to the European Commission’s order for it to divest Grail; StrokeDX won a global innovation competition; and the US Food and Drug Administration approved expanded labeling for Boston Scientific’s WaveWriter Alpha to include painful diabetic peripheral neuropathy.
You may also be interested in...
Exec Chat: Medtronic’s Goodheart Talks About COVID, AI, Diversity, TAVR And More
Medtech Insight sat down with Nina Goodheart, the president of Medtronic’s structural heart and aortic operating unit, to learn more about her experience with the company during the pandemic, the company’s commitment to diversity and inclusion, and the future of structural heart technology.
Icahn’t Believe It Isn’t Over: Investor Sues Illumina
Carl Icahn has stepped up his attempts to take control of Illumina. This time the legendary corporate raider is demanding certain board members cover the costs of the failed Grail acquisition.
Digital Health Roundup: HLTH, LSX, AdvaMed; FDA And Pre-Determined Change Control Plans
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with behavioral health experts on implementing AI solutions to help ease the administrative burden on clinicians as well as recent coverage from the LSX Congress USA and HLTH conferences. Reed Miller discusses findings of EY’s annual pulse of the medtech industry report and Hannah Daniel discusses FDA guidance on regulating AI/ML.